Colorectal Cancer

Conserve precious colon samples and get your IHC right the first time with Proteintech’s expansive library of kits and IHC-compatible antibodies.

---

Introduction

Colorectal cancer (CRC) is the third most common form of cancer worldwide, with men having a slightly higher incidence rate compared to women. Risk for developing colorectal cancer usually increases with age and can be attributed to inherited genetic mutations along with other comorbidities such as diabetes, IBD, obesity, poor diet, and an inactive lifestyle. While it can be treated when in its localized state, colorectal cancer does have a high tendency for recurrence after surgery. Additionally, detection of CRC can also be a challenge due to non-distinct symptoms that often overlap with other abdominal conditions, a delay in referring patients for additional screening, and a lack of colonoscopy resources, particularly in vulnerable communities. Proteintech offers a broad portfolio of IHC resources to help with better identification of the molecular targets associated with CRC disease origin, progression, and treatment.

Featured Markers

APC

Adenomatous polyposis coli (APC) is an antagonist of the Wnt signaling pathway. It typically binds with and triggers the degradation of the beta-catenin transcription factor. This leads to suppressed proliferation, increased cell differentiation, and in some cases, apoptosis. APC is affected by loss of function mutations in up to 80% of all CRC cases that result in truncated proteins. These truncated forms of APC help to promote the progression of CRC as they are unable to inhibit beta-catenin from reaching the nucleus and in-turn can promote the localization of anti-apoptotic proteins, such as Bcl-2, to the mitochondria. Due to its important tumor-suppressing functions, restoring APC activity has become an area of interest in the development of new, targeted CRC therapies.

 Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 19782-1-AP (APC Antibody) at dilution of 1:50.

P27/CDKHN1B

P27 is an inhibitor of the cyclin E/Cdk2 complex that allows cells to progress from G1 to S phase of the cell cycle. The accumulation of p27 in the cell typically causes it to remain in a quiescent state until pro-mitogenic events trigger p27 phosphorylation and subsequent degradation. The loss of p27 expression has been associated with colon cancer, resulting in uncontrolled cell growth and poor overall prognosis. P27 is often affected by alternative phosphorylation events that result in it being translocated to the cytoplasm and unable to prevent DNA replication. Proteintech’s p27 antibody is one of the top-cited on the market, featured in over 150 publications worldwide.

Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 25614-1-AP (p27; KIP1 antibody) at dilution of 1:200 (under 10x lens).

Osteopontin

Osteopontin (OPN) is part of the SIBLING family of proteins that play a role in forming the extracellular matrix of bone and dentin. However, unlike the other members of this family, OPN can be expressed in a wider variety of tissues and can have pleiotropic function in several different cancers including breast, lung, liver, stomach, and colon. Within the context of colon cancer, OPN promotes metastasis through inducing the expression of invasion-promoting genes and upregulating the expression of ECM-degrading proteins, such as MMPs and uPA. There are also studies to suggest that OPN might be able to increase stem-like qualities in colorectal cancer cells, giving them better regeneration capabilities and the potential to become drug-resistant. Proteintech’s OPN antibody is one of the top-cited on the market, featured in over 180 publications and counting.

Immunohistochemical analysis of paraffin-embedded human colon cancer using 22952-1-AP (Osteopontin antibody) at dilution of 1:50 (under 10x lens).

Antibodies for Colorectal Cancer Research

Function	Marker	PTG Catalog
Angiogenesis	ANTXR1	15091-1-AP
	PAI-1	13801-1-AP
Cell Cycle, Growth, and Proliferation	CDKN1B/p27	25614-1-AP
	COX2	12375-1-AP
	ERK1/2	11257-1-AP
	EYA4	24691-1-AP
	HDGF	11344-1-AP
	Lactoferrin	10933-1-AP
	LGALS1	11858-1-AP
	MCC	11525-1-AP
	P53	60283-2-Ig
	SMAD4	10231-1-AP
	ST13	26581-1-AP
	STAT3	10253-2-AP
	TK1	67787-1-Ig
Cell Survival	APC	19782-1-AP
	BAX	50599-2-Ig
	BCL2	12789-1-AP
	CSE1L	22219-1-AP
	NNMT	15123-1-AP
Cell Stemness	Beta catenin	51067-2-AP
	BMI1	10832-1-AP
	CD117	18966-1-AP
Metastasis	AGO2	67934-1-Ig
	AREG	16036-1-AP
	ARG1	16001-1-AP
	BRAF	20899-1-AP
	Cytokeratin 20	17329-1-AP
	FOXO3A	10849-1-AP
	G6PD	25413-1-AP
	IGFR1	20254-1-AP
	ITGB4	21738-1-AP
	KPNA2	10819-1-AP
	LOXL2	67139-1-Ig
	MMP1	10371-2-AP
	MMP2	10373-2-AP
	MUC1	23614-1-AP
	Osteopontin	22952-1-AP
	PTEN	22034-1-AP
	SERCA2	67248-1-Ig
	STMN1	11157-1-AP
	TPT1	10824-1-AP
	UCHL1	14730-1-AP

IHC Kits for Colorectal Cancer Research

Function	Marker	PTG Catalog
Angiogenesis	PAI-1	KHC0461
Cell Cycle, Growth, and Proliferation	CDKN1B/p27	KHC0773
	COX2	KHC0770
	ERK1/2	KHC0917
	EYA4	KHC0767
	HDGF	KHC0898
	LGALS1	KHC0826
	MCC	KHC0759
	P53	KHC0079
	ST13	KHC0849
	STAT3	KHC0761
	TK1	KHC0765
Cell Survival	BAX	KHC0768
	BCL2	KHC0012
	CSE1L	KHC0779
Cell Stemness	Beta catenin	KHC0008
	BMI1	KHC0296
	CD117	KHC0818
Metastasis	AGO2	KHC0797
	AREG	KHC0808
	Cytokeratin 20	KHC0034
	FOXO3A	KHC0815
	G6PD	KHC0876
	IGFR1	KHC0737
	ITGB4	KHC0800
	KPNA2	KHC0799
	LOXL2	KHC0823
	MMP1	KHC0804
	MMP2	KHC0762
	MUC1	KHC0304
	Osteopontin	KHC0782
	PTEN	KHC0280
	STMN1	KHC0841
	TPT1	KHC0874
	UCHL1	KHC0054

Sources

American Cancer Society. Colorectal Cancer Facts & Figures 2020-2022. Atlanta: American Cancer Society; 2020.

Amilca-Seba, K., Sabbah, M., Larsen, A. K., & Denis, J. (2021). Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications. Cancers, 13(15), 3793. https://doi.org/10.3390/cancers13153793

Bochis, O. V., Irimie, A., Pichler, M., & Berindan-Neagoe, I. (2015). The Role of Skp2 and its Substrate CDKN1B (p27) in Colorectal Cancer. Journal of Gastrointestinal and Liver Diseases, 24(2), 225–234. https://doi.org/10.15403/jgld.2014.1121.242.skp2

Hankey, W., Frankel, W. L., & Groden, J. (2018). Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. Cancer and Metastasis Reviews, 37(1), 159–172. https://doi.org/10.1007/s10555-017-9725-6

Vacante, M., Borzì, A. M., Basile, F., & Biondi, A. (2018). Biomarkers in colorectal cancer: Current clinical utility and future perspectives. World Journal of Clinical Cases, 6(15), 869–881. https://doi.org/10.12998/wjcc.v6.i15.869

Vega, P. C., Valentín, F., & Cubiella, J. (2015). Colorectal cancer diagnosis: Pitfalls and opportunities. World Journal of Gastrointestinal Oncology, 7(12), 422. https://doi.org/10.4251/wjgo.v7.i12.422